HCW Biologics Inc. (HCWB)
NASDAQ: HCWB · Real-Time Price · USD
2.410
-0.650 (-21.24%)
At close: Nov 18, 2025, 4:00 PM EST
2.470
+0.060 (2.49%)
After-hours: Nov 18, 2025, 5:45 PM EST

HCW Biologics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 20202019
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019
0.422.572.846.72-4.1
Upgrade
Revenue Growth (YoY)
-87.93%-9.68%-57.73%---
Upgrade
Cost of Revenue
0.341.612.284.14--
Upgrade
Gross Profit
0.080.960.562.59-4.1
Upgrade
Selling, General & Admin
6.922.8513.448.415.32.75
Upgrade
Research & Development
5.066.297.599.258.077.17
Upgrade
Operating Expenses
11.9630.4426.2817.6713.379.92
Upgrade
Operating Income
-11.87-29.48-25.72-15.08-13.37-5.82
Upgrade
Interest Expense
-0.87-0.63-0.28-0.13--
Upgrade
Interest & Investment Income
-----0.02
Upgrade
Other Non Operating Income (Expenses)
-0.090.090.760.49-0.06-
Upgrade
EBT Excluding Unusual Items
-12.83-30.02-25.24-14.71-13.43-5.8
Upgrade
Gain (Loss) on Sale of Investments
0.78-0.25-0.19--
Upgrade
Other Unusual Items
----0.57-
Upgrade
Pretax Income
-12.05-30.02-24.99-14.9-12.86-5.8
Upgrade
Net Income
-12.05-30.02-24.99-14.9-12.86-5.8
Upgrade
Preferred Dividends & Other Adjustments
-10.15----1.27
Upgrade
Net Income to Common
-1.9-30.02-24.99-14.9-12.86-7.07
Upgrade
Shares Outstanding (Basic)
211100
Upgrade
Shares Outstanding (Diluted)
211100
Upgrade
Shares Change (YoY)
62.33%7.97%0.30%90.84%296.07%10.56%
Upgrade
EPS (Basic)
-1.26-30.96-27.83-16.64-27.41-59.70
Upgrade
EPS (Diluted)
-14.71-30.96-27.83-16.64-27.41-59.70
Upgrade
Free Cash Flow
-12.98-14.49-28.72-20.66-11.02-10.62
Upgrade
Free Cash Flow Per Share
-8.60-14.94-31.97-23.07-23.49-89.62
Upgrade
Gross Margin
20.00%37.38%19.72%38.48%-100.00%
Upgrade
Operating Margin
-2812.94%-1148.50%-904.96%-224.32%--142.07%
Upgrade
Profit Margin
-449.83%-1169.70%-879.52%-221.67%--172.54%
Upgrade
Free Cash Flow Margin
-3076.68%-564.48%-1010.51%-307.36%--258.99%
Upgrade
EBITDA
-10.3-28.3-24.58-14.49-12.82-5.25
Upgrade
EBITDA Margin
----215.55%--128.10%
Upgrade
D&A For EBITDA
1.571.181.140.590.540.57
Upgrade
EBIT
-11.87-29.48-25.72-15.08-13.37-5.82
Upgrade
EBIT Margin
----224.32%--142.07%
Upgrade
Revenue as Reported
-----4.1
Upgrade
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q